Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Then move on if you don’t see it, cut your losses and don’t be trolling. Re LEDs, if are as you say, your in the space, you would know that’s there has been a huge move to leds over the last 12 months as quality has improved.
If the sltk led is as good as it’s hid product (in category) then this should result in a 4x revenue increase which is a real positive. Throw in their other new products along with their processing and grow in AZ and I see a real strong 2019
That’s a fair point but I believe they will be nasdaq bound shortly and at that point bigger buyers will come in. Think there’s a big shirt here that under the right conditions could be triggered.
Doesn’t matter overall as there’s too many positive signs and I see this fundamentally going up in the short term
Don’t see an uplist problem for gryn as of yet, they only started the process last week and given holidays and everything, it would be unrealistic to get the approval that quickly.
As it stands, they look like running anyway as word is starting to get out about them
Always the negative 420. Stock is up 120% from the lows and Najarian given his connections opens up
Doors for any company! He didn’t come on board because the company was going to fail! Why risk his reputation. Think we see big things from sltk in the coming months
Given you are in the space, I’m sure you are aware that a lot of the new permits are mandating LEDs hence the move into LED by SLTK, I know of 2 companies currently testing them with strong results. The exciting thing about LEDs from a shareholder perspective is that LEDs are much priever than HID hence increased revenues and hopefully increased profits. Big 12 months ahead for sltk if their new products take off and the AZ project starts providing revenue.
Added to that Pete Najarian joint only opens up bigger business and funding doors so a good time for this company
Have been in this since 45c and took a lot of profit in the $3 range before loading back in again. Thanks for the advice, better to be in the games instead of sitting on the sidelines watching and hoping people lose money like you do!
If you read correctly, majority of warrants are $1.50 plus.
Share structure is very tight for otc so a few million warrants over a 6-12 month period is irrelevant if they execute and generate revenue. I always find it funny when people point out flaws in companies raising money and how they do it. That’s what otcb companies do and this one is unique in that it has a product that sells.
I read the S1, multiple times. YV funding (previously announced ) nothing else in there so what’s your point
Revenue minus costs equals profits. Business 101!
They report 30% margins on their lighting so if they do 9m then they end up
With 3m (not difficult math) then the company running costs come out of the 3m!
I’m looking at their going into the touch the plant side and the revenues that will generate along with a recovery in their core business 2nd half of this year. Bargain prices here for a company like this with real award winning products
You obviously don’t read much, they just won a top industry lighting award for best products!
The industry as a whole has been crucified in the first 6 months of the year with a pickup been seen in the 2nd half. Scott’s miracle grow MJ arm was down 60% year on year and the sacked their entire sales force.
They entire market (mj) has sold off and will bounce again historically in October. I’m expecting a strong 2nd half of the year and looking at other revenue coming from their touch the plant side of things.
If the above happens then this is bargain town here
You would need to explain that logic as it’s a pretty broad statement not backed up by anything ?
All in good time, you guys are used to the P&D world of pink land. This is a future (not too distant) upper tier stock and company and because of that, it’s not a rushed job.
Take a look at their financials and just look at the patent values, now let’s se what happens next
?Can you give me some info please? Took a small position last week.?
?How much money does company have? How many doctors are signed up? What’s the procedure cost and how much profit, how do the raise money for the clinical trials? Any other info appreciated re the patents $celz?
I believe it’s even bigger than the numbers released as that was of March 18.
I feel this is a completely unknown company and stock and by the end of year it will be one of the big winners of the year. Just look at who the main players are. Forget about the president and CEO, they are baby sitting this until one of the really big guys comes in
Whatever the term, the answer is still the same
The “runners” as you put it have been buying this stock for over a year and I’d imagine have zer powder left . This now is being turned over to the big boys who after carful analysis will not buy 100k but want to buy 10m.
That doesn’t happen on Monday, if it adds up that happens over the next 2 months.
All the audit has done is make existing shareholders happy, now the company has to articulate its plans and story to the street as a whole. If they do it correctly (which I believe they will) then it goes well past this years highs later in the summer, then a Nasdaq move and the really heavy hitters come to play. What speeds this whole thing up is if they get a deal with a big pharma company shortly, then stock explodes.
Either way, the Audit with the patent valuation and the increasing revenue validates the company
News came out Friday late and market doesn’t instantly react to news. The company now has to articulate what it intends to do with the patents, go it alone or hook up with Big pharma
2B in patents can’t be perceived as bad news!
Also revenue growth is ramping up and if that continues then again it’s great news. What’s needed it clear explanation from the company as to its plans for the patents and a clear outline of the revenue potential. That’s what’s going to make this life off. I’m sure we will get this in the short term. Next up nasdaq , patent plan and revenue projections. I’d assume that LHA and Wilson Sonsini have all this in hand, after all they are the best in the business
FYI
Independent valuations (as this one is) are generally kept on the conservative side as the valued will always err on the side of caution. However I’ll take a $1.4B patent valuation right now which no doubt will go up from here.
Add in growing revenues, stellar board, world class attorneys and a Nasdaq move, I’d say we have much much better days ahead
Guess yesterday’s news clears up your concerns ! O and The $1.4Billion in independently valued assets is great as well. All in all, a great way to end the week.
I’d expect more audits from further back to be released in preparation for Nasdaq.
Read one of my first postson this , it’s the real deal
By all means supply that info as I don’t believe the audit re the well being of this company is known yet?
Some weekend reading for anyone who didn’t follow my links re who is involved in this company.
Not that impressive really!!
Michael Dey, Ph.D
CEO of Predictive Therapeutics / Director
Michael Dey, Ph.D. is a member of the Board of Directors of Predictive Technology Group, Inc. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED’s subsidiaries.
In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business. As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.
Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology
Timothy W. Lacy
Chief Sales Officer
As a proven leader in the healthcare industry for over 27 years, Tim now serves as one of Predictive’s leaders. Playing a key role in the overall commercialization of Predictive Biotech and Predictive Therapeutics, he’s driving the evolution of a new product, marketing and sales approach across the healthcare continuum.
Before bringing his talents to Predictive, Tim served as a senior executive for Fortune 100 companies UnitedHealth Group and Walgreens for 20 years, where he managed national sales, sales operations and corporate development.
Dr. John C. Nelson. M.D., M.P.H
Chief Medical Officer
Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.
Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society, and the Utah Medical Association. Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ). As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.
Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education. As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.
John E. Sorrentino
Chairman of Scientific Advisory Board
John E. Sorrentino chairs the Predictive Therapeutics’ Scientific Advisory Board. Predictive Therapeutics, a wholly owned subsidiary of Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Sorrentino is Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer and brings his vast experience in R&D and clinical laboratory management to the Predictive Therapeutics’ Advisory team.
Sorrentino has over 35 years of senior management experience in the life sciences. Focused on improving public health, he has held leadership roles in private, and public companies, as well as government and non-profit institutions. Prior to joining Wyeth, later acquired by Pfizer, 14 years ago, Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services. Sorrentino’s expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues.
Mr. Sorrentino experiences in clinical testing and women’s health will be an invaluable addition to the Company’s current team of experts and its mission to effectively treat endometriosis
Dr. Hugh S. Taylor
Scientific Advisory Board
Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale University, brings extensive clinical research and development expertise in endometriosis and women’s health to PRED’s Scientific Advisory Board team.
Dr. Taylor’s many accomplishments include Anita O’Keeffe Young Professor and Chairs Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics, and Gynecology at Yale-New Haven Hospital. He teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University. His clinical interests include endometriosis, infertility, implantation, Asherman’s syndrome, menopause and uterine anomalies
.Also, Dr. Taylor, a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology, received eight National Institutes of Health research grants. Dr. Taylor published more than 300 articles in leading medical journals, continues as the Editor-In-Chief of Reproductive Sciences, and elected to the membership of the National Academy of Medicine.
Dr. Taylor received his undergraduate training at Yale University and his medical degree from the University Of Connecticut School Of Medicine. He completed his residency in obstetrics and gynecology at Yale. His postdoctoral training included a fellowship in reproductive endocrinology and infertility, as well as, a fellowship in molecular biology, both at Yale.
I don’t know if they fired Yes Internstional but I do know the LHA is one of the worlds leading bio tech IR groups. Just another top notch group that would run a mile if they were worried about this company
Not interested in this Ferguson guy , he’s in apresidents role and isn’t a major part of this.
Here’s the names you should focus on, do a bit of research and get back to me
Wilson sonsini
John sorintini
Tim lacy
I have more for you when you research those.
If your one negative is Ferguson, I’ll raise you my names as they far outweigh your negative
I only go on the facts
Hi All, disclaimer. I have amassed a sizable position in PRED over the last 6 months so am long but I don't believe in stories without research. hopefully you find this useful.
Take the time to look through the sites below and educate yourself to what you have. it has the potential to be huge.
Mothership http://predtechgroup.com/
Subs
http://predrx.com/
http://predictivebiotech.com/
OS share count 200m shares, Float 18m shares (most of it held by insiders.
Soon to be audited and per CEO in a public forum heading to Nasdaq
Presentation here
http://wsw.com/webcast/ldmicro14/pred/
Corporate council Wilson Sonsini Goodrich and Rosati (One of the worlds leading Pharma attorneys
IR http://www.lhai.com/ (again one of the worlds leading IR firms
Websites and social media being totally rebranded
Read who has joined and who is running this company
http://predtechgroup.com/press/
This is potentially a multi billion dollar company (think Phizer if you came across them at 5c a share)
As for insiders selling in the form of T trades. Totally false. Form Ts are reflective of the trading for that particular day and can be buys or sells. This notion of form Ts being used by insiders to sell stock is bogus https://www.investopedia.com/terms/f/formt.asp
In review, take an hour, look through the above and then make a decision, to me, this is potentially a diamond hidden in the pinks and we will know more when the audit comes out and this starts to become transparent. The guys involved in this are proven world class individuals who work/worked in some of the biggest bio techs in the world, supported by the best attorneys. This is not a scam as has been alluded to.
Will be interesting to see if the upward trend from yesterday continues today, if it does, it would suggest that there may be news on the way. Alternatively it may be pushed back down again. Nicer for longs to have it trend back up a bit after what has been a depressing few months
Went up on light volume, wouldn’t read too much into it just yet
The spread in a stock like this is totally unrelated to the increased shares in the float! 9m shares is more than adequate for a tight spread, 18m shares does t alter that. 18m shares in a biotech float that states is going to Nasdaq is small! It needs many more shares in the float to be of interest to the larger players who may be interested in this after they file audit and uplist. Again I state, increased float does not mean it’s actively in the market.
Here’s my earlier DD post, increased float or not, the basic fundamentals suggest that something big is brewing here, too many quality people and organizations lining up. Easy to fool one high profile guy but not all of the guys who have joined plus the attorneys and IR team. Check them out
Hi All, disclaimer. I have amassed a sizable position in PRED over the last 6 months so am long but I don't believe in stories without research. hopefully you find this useful.
Take the time to look through the sites below and educate yourself to what you have. it has the potential to be huge.
Mothership http://predtechgroup.com/
Subs
http://predrx.com/
http://predictivebiotech.com/
OS share count 200m shares, Float 18m shares (most of it held by insiders.
Soon to be audited and per CEO in a public forum heading to Nasdaq
Presentation here
http://wsw.com/webcast/ldmicro14/pred/
Corporate council Wilson Sonsini Goodrich and Rosati (One of the worlds leading Pharma attorneys
IR http://www.lhai.com/ (again one of the worlds leading IR firms
Websites and social media being totally rebranded
Read who has joined and who is running this company
http://predtechgroup.com/press/
This is potentially a multi billion dollar company (think Phizer if you came across them at 5c a share)
As for insiders selling in the form of T trades. Totally false. Form Ts are reflective of the trading for that particular day and can be buys or sells. This notion of form Ts being used by insiders to sell stock is bogus https://www.investopedia.com/terms/f/formt.asp
In review, take an hour, look through the above and then make a decision, to me, this is potentially a diamond hidden in the pinks and we will know more when the audit comes out and this starts to become transparent. The guys involved in this are proven world class individuals who work/worked in some of the biggest bio techs in the world, supported by the best attorneys. This is not a scam as has been alluded to.
Just because it’s in DTCC doesn’t mean it’s being sold. This is old placement stock and as such is at higher prices. Some of it may have been sold but it’s speculstion as to whether it is it not. Stating that it’s being sold without actual info to back it up is disingenuous and misleading.
You are entitled to your opinion but without proof, it’s just that, an opinion, no better or worse than my own.
The DD I posted earlier is fact based and everyone can make pmtheir own minds as to its merit or not
Hi All, disclaimer. I have amassed a sizable position in PRED over the last 6 months so am long but I don't believe in stories without research. hopefully you find this useful.
Take the time to look through the sites below and educate yourself to what you have. it has the potential to be huge.
Mothership http://predtechgroup.com/
Subs
http://predrx.com/
http://predictivebiotech.com/
OS share count 200m shares, Float 18m shares (most of it held by insiders.
Soon to be audited and per CEO in a public forum heading to Nasdaq
Presentation here
http://wsw.com/webcast/ldmicro14/pred/
Corporate council Wilson Sonsini Goodrich and Rosati (One of the worlds leading Pharma attorneys
IR http://www.lhai.com/ (again one of the worlds leading IR firms
Websites and social media being totally rebranded
Read who has joined and who is running this company
http://predtechgroup.com/press/
This is potentially a multi billion dollar company (think Phizer if you came across them at 5c a share)
As for insiders selling in the form of T trades. Totally false. Form Ts are reflective of the trading for that particular day and can be buys or sells. This notion of form Ts being used by insiders to sell stock is bogus https://www.investopedia.com/terms/f/formt.asp
In review, take an hour, look through the above and then make a decision, to me, this is potentially a diamond hidden in the pinks and we will know more when the audit comes out and this starts to become transparent. The guys involved in this are proven world class individuals who work/worked in some of the biggest bio techs in the world, supported by the best attorneys. This is not a scam as has been alluded to.
They keep a low profile and go about there business which is growing yrarvon year. I feel they are really undervalued and with a bit more exposure will catch up With its peers. Solid business, great cap structure, good management. This is a silent winner
If you believe that, by the way I agree with you the have. Look at $sltk Solis Tek, provides lights and nutrients to the entire sector. Under the radar from the markets point of view but very well respected with growers. Quirky growing but a Big Bang coming here in Q1. KSHB trading 80 times revenue and sltk trading at 7 times revenue, lot of upside and unless earnings are amazing for KSHB, it’s over extended at this time. Though I do believe it’s a great company and I have shares from a few months back in the 1.90s, sold half in the $5s didn’t see it going this far
Third day in a row in the top 3 of @MarijuanaIndex $sltk leading the way with great products, Taglich brothers put $3 target based on $11m revenue 2018, taglichbrothers.com/equityuniverse… they will blow that away. Institutional financing completed all good for this gem.
Bright future here and a lot of room to run
What happens next week!
Sltk Q2 results out,
Highlights
Revenues of $2.44 million; up 15% from 2016
Gross Profit of $920,000 up 15% from 2016
Gross Margin of 37%
A strong quarter and showing consistent growth, with new states coming in board, I expect the revenue to continue to crank up
Does he have real companies or just the usual hype?
Is he not a new ambulance chaser, younger version of the iceman?
Agree re the iceman but having looked at this company and looked at the people around it, it ticks all the boxes. Plus it's actually doing strong revenues, not like the P&D stuff he usually talks about!
This company will grow as the industry grows and nobody doubts Marijuana is here to stay and grow. You need lights and fertilisers so there's the future growth of sltk laid out in front of us
Sltk have been selling to the space for 10 years, the mj space is only getting bigger no matter what sessions does, the states will fight him tooth and nail. Bottom line, apart from the initial talk, there has been zero action and that will continue to be the case. I see sktk as the leaders in this space and revenues continue to grow with a butout in the next 2 years by a big player looking to enter the market